Please use this identifier to cite or link to this item: https://hdl.handle.net/1959.11/59650
Title: Targeting P2X7 receptors as a means for treating retinal disease
Contributor(s): Fletcher, Erica L (author); Wang, Anna Y (author); Jobling, Andrew I (author); Rutar, Matthew V (author); Greferath, Ursula (author); Gu, Ben (author); Vessey, Kirstan A  (author)orcid 
Publication Date: 2019
DOI: 10.1016/j.drudis.2019.03.029
Handle Link: https://hdl.handle.net/1959.11/59650
Abstract: 

Age-related macular degeneration and glaucoma are the commonest causes of irreversible vision loss in industrialized countries. The purine ATP is known to regulate a range of cellular functions in the retina via its action on P2 receptors, especially the P2X7 receptor. Although agents that attenuate P2X7 receptor function have been in development for many years, no compound is currently approved for the treatment of eye disease. However, newer compounds that cross the blood-brain barrier could have potential to reduce vision loss. This review will outline recent information relating to the role of P2X7 in age-related macular degeneration and glaucoma and, subsequently, we will discuss recent developments for attenuating P2X7 receptor function.

Publication Type: Journal Article
Source of Publication: Drug Discovery Today, 24(8), p. 1598-1605
Publisher: Elsevier Ltd. * Trends Journals
Place of Publication: United Kingdom
ISSN: 1878-5832
1359-6446
Fields of Research (FoR) 2020: 3209 Neurosciences
Peer Reviewed: Yes
HERDC Category Description: C1 Refereed Article in a Scholarly Journal
Appears in Collections:Journal Article
School of Science and Technology

Show full item record

SCOPUSTM   
Citations

24
checked on Dec 7, 2024
Google Media

Google ScholarTM

Check

Altmetric


Items in Research UNE are protected by copyright, with all rights reserved, unless otherwise indicated.